Transaminase mutant and application thereof in preparation of oxaliplatin chiral intermediate

By designing the aminotransferase mutant and using two aminotransferase catalysts, the complex preparation, high cost and pollution of oxaliplatin chiral intermediates in traditional chemical methods are solved, and high efficiency, low cost and high purity preparation is achieved, and the reaction conditions are mild , the three waste production is low and has good application prospects.

CN118979022APending Publication Date: 2024-11-19TIANJIN PHARMACN MEDICAL TECH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410817201.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-24
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The synthetic route of traditional chemical methods for producing chiral amine compounds is complex, with high cost, low yield and optical purity of the products, and serious environmental pollution. Especially when preparing oxaliplatin chiral intermediates, existing methods It is difficult to achieve high efficiency, low cost and high purity preparation.

Method used

By designing the transaminase mutant, two transaminases were used as catalysts to catalyze 1,2-cyclohexanediamine in the same system, and a series of reactions were used to generate high-purity (1R,2R)-trans-1,2-cyclohexanediamine in a high-purity (1R,2R)-trans-1,2-cyclohexanediamine through a series of reactions. amine, realizes the directional and efficient preparation of oxaliplatin chiral intermediates, the reaction conditions are normal temperature and normal pressure, the aqueous phase reaction, and the yield of the three wastes is low.

Benefits of technology

The preparation of chiral amine intermediates with high purity (>99.8%) was achieved, which reduced production costs, simple and mild reaction, and low yield of three wastes, and has good application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004908040750000011
    Figure BDA0004908040750000011
  • Figure BDA0004908040750000031
    Figure BDA0004908040750000031
  • Figure BDA0004908040750000041
    Figure BDA0004908040750000041
Patent Text Reader

Abstract

The invention provides a transaminase mutant and application of the transaminase mutant in preparation of an oxaliplatin chiral intermediate. A mutated amino acid sequence of the transaminase mutant has at least one mutation site in an amino acid sequence shown as SEQ ID NO.2: the 24th site, the 61st site, the 120th site, the 123th site and the 414th site. A preferable transaminase mutant as shown in SEQ ID NO.3 is applied to preparation of an oxaliplatin chiral intermediate, two chiral centers of the oxaliplatin intermediate are constructed in a catalysis mode of the transaminase as shown in SEQ ID NO.1 and the transaminase mutant as shown in SEQ ID NO.3, 1, 2-cyclohexanediamine is converted into (1R, 2R)-trans-1, 2-cyclohexanediamine, the process is safe, operation is simple, and the method is suitable for industrial production. The method increases the utilization rate of raw materials, reduces the generation of by-products and isomers, reduces three wastes, reduces the synthesis cost, and is suitable for industrial mass production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biotransformation, and particularly relates to a transaminase mutant and application thereof in preparing an oxaliplatin chiral intermediate. Background Art

[0002] Chiral amines are a class of compounds with a functional group "-NH2" attached to the chiral center. They are an important class of pesticide and pharmaceutical intermediates. For example, the synthesis of neurological drugs, cardiovascular drugs, antihypertensive drugs, anti-infective drugs, etc. all use chiral amines as intermediates. However, the traditional chemical method for producing chiral amine compounds has a complex synthesis route, high cost, harsh reaction conditions, low yield and optical purity of the product, and is also prone to cause serious pollution to the environment.

[0003] Oxaliplatin, also known as Lexadin and Oxalate, has a chemical structure as shown in Formula 1. It was first launched in France in October 1996 and is a third-generation platinum drug. It is used clinically to treat patients with colorectal cancer metastasis after failure of fluorouracil treatment. It can be used alone or in combination with fluorouracil. It is a third-generation new platinum anti-tumor compound after cisplatin and carboplatin, and is the only platinum drug with significant activity against colorectal cancer so far. In addition, oxaliplatin also has good efficacy against small cell lung cancer, non-small cell lung cancer, gastric cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, malignant lymphoma, esophageal cancer, liver cancer and head and neck tumors. Oxaliplatin maintains the cis structure of cisplatin, with platinum as the center, diaminocyclohexane as the retaining ligand, and oxalate as the leaving group. The hydrophobic diaminocyclohexane ligand introduced prevents the binding of repair proteins to DNA, so oxaliplatin becomes the first platinum drug to resist tumor cell resistance. In addition, oxaliplatin has significantly less toxicity to the gastrointestinal tract, liver, kidney, and bone marrow than cisplatin and carboplatin, and is well tolerated.

[0004]

[0005] The compound (1R,2R)-trans-1,2-cyclohexanediamine (CAS: 20439-47-8) shown in Formula 2 is a chiral amine, a key intermediate of oxaliplatin, and can also be used as a starting material for a variety of chiral drugs and fine chemicals. Its production process can be divided into two categories: the first category is to first obtain racemic 1,2-cyclohexanediamine, and then use a splitting method to obtain high chiral purity (1R,2R)-trans-1,2-cyclohexanediamine. For example, patent CN106905100A discloses a method for resolving racemic 1,2-hexanediamine using N-toluenesulfonyl-L-aspartic acid as a resolving agent; for another example, US201616885, JFLarrow et al. (Org. Synth., Coll. 2004, 10, 96), NSKMohan et al. (Journal of the American Chemical Society, 2016, 138, 5968), NSKMohan et al. (Journal of the American Chemical Society, 2019, 141, 1290), FMEReda et al. (Journal of Molecular Liquids, 2017, 241, 308), T. Zhang et al. (Synthetic Communications, 2019, 49, 410), C. Li et al. (Catalysis Letters, 2024, 154, 1420), N. Kiyoshi et al. (Macromolecules, 2012, 45, 8172), K. Mehmet et al. (Tetrahedron, 2013, 69, 349), AY Mohammad et al. (Journal of Molecular Structure, 2019, 1191, 118), F. Arriba et al. (Journal of Organic Chemistry, 2010, 75, 8303) reported a method for preparing (1R, 2R)-trans-1,2-cyclohexanediamine by splitting racemic 1,2-hexanediamine with L-tartaric acid; TE Gilbert et al. (Organic Letters, 2005, 7, 4045) disclosed a method for obtaining (1R, 2R)-trans-1,2-cyclohexanediamine by lipase splitting. Although high-purity trans-1,2-hexanediamine can be obtained by the splitting method, its theoretical yield is only 25%, and it is difficult to achieve a chiral purity of the target configuration product of more than 99.8% through a single splitting.

[0006] Another method for producing (1R, 2R)-trans-1,2-cyclohexanediamine is direct synthesis. For example, H.S. Chong et al. (Tetrahedron Letters, 2015, vol. 56, #7, p. 946-948) disclosed a method for obtaining trans-1,2-hexanediamine by three steps from trans-N, N-dibenzyl-β-aminocyclohexanol as a starting material; M. Chandrasekhar et al. (Tetrahedron Letters, 2000, vol. 41, #51, p. 10079-10083) disclosed a method for obtaining (1R, 2R)-trans-1,2-cyclohexanediamine by a series of reactions using N-benzylcyclohexylaziridine as a starting material and nucleophilic ring opening of aziridine with trimethylsilyl (TMS) azide. However, this type of method often requires chiral auxiliary agents, chiral compounds as starting materials, or precious metal derivatives as catalysts, which results in high production costs. In addition, the reaction process is also relatively complicated, and it is difficult to obtain products with high chiral purity. During the reaction process, dangerous processes such as catalytic hydrogenation, high temperature, and high pressure are often required. The output of "three wastes" is also relatively large. All these have limited the industrial use of the direct synthesis method for preparing trans-1,2-hexanediamine. Summary of the invention

[0007] In view of the deficiencies of the prior art, the present invention provides a transaminase mutant and application thereof in the preparation of an oxaliplatin chiral intermediate.

[0008] The present invention achieves this object through the following technical solutions:

[0009] On one hand, the present invention provides a transaminase mutant, wherein the mutated amino acid sequence has at least one mutation site in the amino acid sequence shown in SEQ ID NO: 2: the 24th, 61st, 120th, 123rd, and 414th positions.

[0010] Preferably, the amino acid sequence of the aminotransferase mutant is as shown in SEQ ID NO.3, or has the mutation site in the amino acid sequence shown in SEQ ID NO.3 and has an amino acid sequence with more than 90% homology with the amino acid sequence shown in SEQ ID NO.3.

[0011] Furthermore, the present invention also provides a recombinant expression vector containing the transaminase mutant gene, with the pET series plasmid as the starting vector.

[0012] Furthermore, the present invention also provides a genetically engineered bacterium for producing the transaminase mutant, wherein the genetically engineered bacterium comprises the recombinant vector, and the host cell is Escherichia coli BL21 (DE3).

[0013] Furthermore, the present invention also provides the use of the transaminase mutant, the recombinant vector, and the genetically engineered bacteria in the preparation of oxaliplatin chiral intermediates.

[0014] In view of the defects of the current method for synthesizing chiral amine intermediates, the present invention provides a method for preparing an oxaliplatin chiral intermediate on the other hand, which uses two different transaminases as catalysts to catalyze 1,2-cyclohexanediamine in the same system, and generates two chiral centers through a series of reactions, thereby achieving directional, efficient and high-purity preparation of the chiral amine intermediate shown in formula 2. The method is safe, environmentally friendly, low-cost, and the produced oxaliplatin intermediate has excellent optical purity. It includes the following steps:

[0015] Step 1: Using 1,2-cyclohexanediamine as a substrate, adding a catalyst containing transaminase and pyruvic acid, converting 1,2-cyclohexanediamine into 2-aminocyclohexanone, the reaction process is shown in Formula 3; after the catalytic reaction is completed, the transaminase is inactivated; the amino acid sequence of the transaminase is shown in SEQ ID NO.1.

[0016]

[0017] Step 2: adding a catalyst comprising the aminotransferase mutant according to claim 2 and isopropylamine, transferring the amino group of isopropylamine to R-2-aminocyclohexanone to form (1R, 2R)-trans-1,2-cyclohexanediamine. The reaction process is shown in Formula 4.

[0018]

[0019] S-2-aminocyclohexanone that does not participate in the catalytic reaction can form 2-aminocyclohexanone through spontaneous enol interconversion and continue to become a substrate for the transaminase mutant, as shown in Formula 5.

[0020]

[0021] In order to prevent reversible reaction, the molar amount of pyruvic acid is 2 to 20 times of 1,2-cyclohexanediamine. Preferably, the molar amount of pyruvic acid is 4 to 6 times of 1,2-cyclohexanediamine.

[0022] In step 1, the transaminase is inactivated by heating to above 60°C, adjusting the pH to less than 4 or greater than 11, or ultrafiltration. Preferably, the transaminase can be inactivated by heating or adjusting the pH to less than 4.

[0023] The molar amount of isopropylamine in step 2 is 2 to 20 times that of 1,2-cyclohexanediamine. Preferably, the molar amount of isopropylamine is 8 to 12 times that of 1,2-cyclohexanediamine.

[0024] Compared with the prior art, the present invention has the following advantages and effects:

[0025] 1. The present invention mutates the transaminase by rational design (based on the spatial structure of the protein similar to that of the wild-type transaminase, individual amino acids in the protein molecule are changed by site-directed mutagenesis or other methods) and overlap extension PCR, recombinant PCR, large primer PCR and circular plasmid PCR. By establishing a transaminase mutant gene library combined with high-throughput enzyme activity screening, a highly active and highly selective transaminase mutant is obtained, and the amino acid sequence of the mutant is SEQ ID NO.3.

[0026] 2. The aminotransferase mutant provided by the present invention has higher selectivity and catalytic activity for the substrate shown in Formula 4. The aminotransferase mutant can convert 40 g / L of the substrate into the product within 6 hours. When detected according to the method described in Example 7, the chiral purity of the product is >99.8%; while the wild-type enzyme can only convert 15 g / L of the substrate into the product within 6 hours, and the chiral purity is 87.4%.

[0027] 3. The method for preparing chiral intermediates of oxaliplatin based on dynamic kinetics provided by the present invention converts 1,2-cyclohexanediamine into (1R,2R)-trans-1,2-cyclohexanediamine. Under the optimal conditions, the molar yield can reach more than 90%, which is much higher than the yield of the resolution method.

[0028] 4. The preparation method of the chiral intermediate of oxaliplatin provided by the present invention converts 1,2-cyclohexanediamine into (1R,2R)-trans-1,2-cyclohexanediamine by enzyme catalysis. The production conditions are normal temperature, normal pressure, and aqueous phase reaction. The reaction conditions are mild and the output of three wastes is low.

[0029] In summary, the preparation method of the chiral intermediate of oxaliplatin provided by the present invention can effectively convert 1,2-cyclohexanediamine into (1R,2R)-trans-1,2-cyclohexanediamine. The reaction is simple and mild, no waste is discharged, the reaction conversion rate is high, and it has good application prospects. DETAILED DESCRIPTION

[0030] The present invention is further described in detail below in conjunction with embodiments. The following embodiments are for explanation of the present invention but the present invention is not limited to the following embodiments.

[0031] Example 1: Establishment of wild-type transaminase genetic engineering bacteria

[0032] According to the amino acid sequence of the wild-type transaminase protein from Sphingopyxis macrogoltabida included in NCBI (WP_054726400.1, SEQ ID No. 1) and the amino acid sequence of the wild-type transaminase protein from Thermoleptolyngbya sp. M55_K2018_002 (WP_297077611.1, Seq ID No 2), the whole gene fragment was artificially synthesized after sequence optimization, and the gene was inserted into the pET-24a plasmid by NdeI and BamHI endonucleases by a gene synthesis company, and the connected vector was transferred into Escherichia coli BL21 (DE3) to establish a transaminase genetic engineering bacterium.

[0033] Example 2: Obtaining transaminase mutant genes

[0034] Since the three-dimensional structure of the wild-type transaminase described in SEQ ID No.2 has not been revealed yet. The present application found through Blast comparison of the wild-type gene sequence that it has a consistency of 47.75% with the transaminase derived from Pseudomonas sp.Strain AAC (PDB: 4uhn). Therefore, the three-dimensional structure of the enzyme was analyzed with reference to the analysis, and the binding of the substrate shown in Formula 5 with the protein was simulated by Docking, and finally, the amino acids that may be related to substrate binding, PLP binding, and proton transfer were selected as mutant amino acids through Pymol analysis.

[0035] In addition to the above rational design, the present application also uses the method of random mutation of error-prone PCR to carry out protein engineering of transaminase. When error-prone PCR amplifies the target gene through DNA polymerase, the reaction conditions are adjusted (including increasing the magnesium ion concentration, adding manganese ions, changing the concentration of four dNTPs in the system, or using low-fidelity DNA polymerase, etc.) to change the mutation frequency during the amplification process, thereby randomly introducing mutations into the target gene at a certain frequency to obtain random mutants of protein molecules.

[0036] This example uses a lower fidelity Taq polymerase and uses Mn 2+ Replacement of natural cofactor Mg 2+ To increase the probability of error, the design system is as follows:

[0037] The 50μL PCR system is as follows:

[0038]

[0039] Wherein: the transaminase template gene is constructed by amplifying the transaminase gene by PCR according to the method in Example 1 and inserting the gene into the pET-24a plasmid; the primer design is designed according to the upstream and downstream sequences of the target gene in the recombinant plasmid constructed in Example 1.

[0040] The PCR reaction conditions were as follows: pre-denaturation at 95°C for 2.5 min; denaturation at 94°C for 15 s, annealing at 53°C for 30 s, and extension at 72°C for 30 s, for a total of 35 cycles; extension at 72°C for 10 min, and cooling to 4°C.

[0041] The obtained PCR amplification product was connected to the pET-24a vector and transformed into Escherichia coli BL21 (DE3) to establish a transaminase gene mutation library.

[0042] The extended aminotransferase mutant is expressed by using Escherichia coli BL21 (DE3) as a host and pET-24a plasmid as a vector. The amino acid sequence of the aminotransferase mutant is an amino acid sequence in which the amino acid sequence shown in SEQ ID NO.2 is mutated; the mutated amino acid sequence has at least one mutation site in the amino acid sequence shown in SEQ ID NO.2: the 24th, 61st, 120th, 123rd, and 414th positions; the amino acid sequence of the aminotransferase mutant has the mutation site in the mutated amino acid sequence and has more than 90% homology with the mutated amino acid sequence.

[0043] Furthermore, a high-activity mutant was obtained by high-throughput screening using the enzyme activity detection method described in Example 5, and its amino acid sequence is shown in SEQ ID NO.3.

[0044] Example 3: Small-scale production of wild-type aminotransferase and aminotransferase mutants in shake flasks

[0045] The Escherichia coli (containing the transaminase mutant gene) containing the recombinant plasmid constructed in Examples 1 and 2 was inoculated into 100 mL LB medium (peptone 10 g / L, yeast extract 5 g / L, NaCl 10 g / L, pH 7.2) containing kanamycin (50 μg / mL). Cultured in a shaker, shaking at 37°C, 210 rpm, and cultured for 16 hours. Then transferred at a ratio of 1:100, placed in 100 mL LB medium containing kanamycin, and cultured under the same shaking conditions, and the absorbance value (OD600) of the bacterial solution at 600 nm was measured regularly to monitor the growth density of the bacteria. When the OD600 of the culture was 0.6-0.8, isopropyl β-D-thiogalactoside (IPTG) was added at a final concentration of 0.8 mM to induce the expression of the target transaminase gene, and the induction culture was overnight (≥16 hours). The mixture was centrifuged at 10,000 rpm and 4°C for 10 min, the supernatant was discarded, the cell pellet was resuspended in pre-cooled 50 mM Tris-HCl buffer (pH 8.5) at 200 g / L, ultrasonically disrupted, and then centrifuged at 13,000 rpm and 4°C for 30 min. The supernatant, i.e., the crude enzyme solution, was collected and stored at -20°C.

[0046] Example 4: Fermentation production of transaminase and transaminase mutants

[0047] Fermentation scheme: The Escherichia coli constructed in Examples 1 and 2 and the recombinant Escherichia coli (containing the mutant transaminase gene) were inoculated into 400mL LB medium (containing kanamycin 50μg / mL) with a single microbial colony, and cultured overnight (≥5 hours) at 37°C and 210rpm with shaking, and then fermented in a 30L fermenter: the seed liquid was inoculated with 15L fermentation medium at a 2% inoculation rate, and the fermentation liquid was maintained at pH=7.0-7.2 by adding ammonia water, the tank temperature was 37°C, the stirring speed was 300-900rpm, and the dissolved oxygen was controlled at about 30% during the process, and the air flow rate was 1:1-2vvm. After culturing for 8 hours, IPTG (final concentration 0.8mmol / L) was added to induce the expression of transaminase, the tank temperature was adjusted to 22°C, and the fermentation was continued for 12-16 hours. During the fermentation process, a feed solution (glucose 200g / L, yeast extract 100g / L, pH7.2) was added to maintain the growth of the culture. After the fermentation is completed, the culture is concentrated to a wet weight of 500 g / L by a ceramic membrane, and then the culture is homogenized and broken by a high-pressure homogenizer. After the fermentation broth is broken, polyethyleneimine with a final concentration of 2 g / L and 150 g / L diatomaceous earth are added and stirred for 30 minutes. After the flocculation and sedimentation are completed, the culture is filtered with a filter cloth covered with diatomaceous earth. The filtered enzyme solution is filtered and concentrated with an ultrafiltration membrane to prepare a crude enzyme solution of transaminase or transaminase mutant and stored at -20°C.

[0048] Example 5: Determination of transaminase activity

[0049] The transaminase activity assay system is as follows:

[0050] 50mM Tris-HCl buffer solution, including 10g / L of the substrate shown in formula 3 (determination of the transaminase shown in SEQ ID No.1) or formula 4 (determination of the transaminase shown in SEQ ID No.2 or the transaminase mutant shown in SEQ ID No.3), 30g / L pyruvate (determination of the transaminase shown in SEQ ID No.1) or isopropylamine hydrochloride (determination of the transaminase shown in SEQ ID No.2 or the transaminase mutant shown in SEQ ID No.3), 1mM 5-pyridoxal phosphate, 5% DMSO, pH 8.5, fixed to 270μL, mixed and added to a 96-well plate. Add 30μL of the crude transaminase enzyme solution (wild-type transaminase or transaminase mutant) or its dilution and mix, then put into a shaker, shake at 30°C and 210rpm for 2h, and detect the remaining raw materials and product generation by HPLC.

[0051] Example 6: Synthesis of (1R,2R)-trans-1,2-cyclohexanediamine

[0052] In a 5L fermenter, add 1.5L 50mM Tri-HCl buffer, then add 1,2-cyclohexanediamine with a final concentration of 40g / L and 185g / L pyruvic acid while stirring, stir evenly, and adjust the pH to 7.5 with sodium hydroxide. Add pyridoxal 5-phosphate with a final concentration of 0.6g / L, stir evenly, and then add 960ml of the crude transaminase solution shown in SEQ ID No.1. Use 50mM Tri-HCl buffer to make up the system volume to 3L and stir at 35℃ for 6h.

[0053] The reaction system was heated to 60°C, stirred for 30 minutes, and then 196 g of isopropylamine hydrochloride was added, the pH was adjusted to 7.5 with sodium hydroxide, 0.1 g / L of 5-pyridoxal phosphate was added and stirred evenly, and then 720 ml of the crude enzyme solution of the aminotransferase mutant shown in SEQ ID No. 3 was added and stirred at 35°C for 6 hours. The remaining raw materials and product generation were detected by HPLC.

[0054] Example 7: Chirality Detection of the Product of Formula 2

[0055] Take 0.05g of (1R,2R)-trans-1,2-cyclohexanediamine obtained in Example 6, add 5mL of dichloromethane, and shake or sonicate until completely dissolved. Add 0.1mL of triethylamine and 0.1mL of benzoyl chloride in sequence, and stir at room temperature for 5 minutes. After the solvent is evaporated, add 3mL of ethanol to dissolve, dilute with mobile phase, and detect chirality as follows.

[0056] Chromatographic column: Chiralpak IC (250 mm × 4.6 mm, 5 μm);

[0057] Mobile phase: n-hexane:ethanol:isopropanol:diethylamine (80:8:12:0.4);

[0058] Flow rate: 0.8ml / min;

[0059] Column temperature: 15°C;

[0060] Detector: UV detector, 230nm.

[0061] After testing, the chiral purity of the (1R, 2R)-trans-1,2-cyclohexanediamine product prepared by the present invention is greater than 99.8%.

[0062] In addition, it should be noted that the specific embodiments described in this specification are not intended to limit the present invention. Those skilled in the art of the present invention may make various modifications or additions to the specific embodiments described or replace them in a similar manner, and as long as they do not deviate from the structure of the present invention or exceed the scope defined in the claims, they shall all fall within the protection scope of the present invention.

Claims

1. A transaminase mutant, It is characterized in that The mutated amino acid sequence has at least one mutation site in the amino acid sequence shown in SEQ ID NO.2: position 24, position 61, position 120, position 123, and position 414.

2. A transaminase mutant according to claim 1, It is characterized in that The amino acid sequence of the aminotransferase mutant is shown in SEQ ID NO.3, or has a mutation site in the amino acid sequence shown in SEQ ID NO.3 and has an amino acid sequence with more than 90% homology with the amino acid sequence shown in SEQ ID NO.

3.

3. A recombinant expression vector, It is characterized in that Contains the transaminase mutant gene according to claim 2, using pET series plasmid as the starting vector.

4. A genetically engineered bacterium for producing the aminotransferase mutant according to claim 2, It is characterized in that The genetically engineered bacteria comprises the recombinant vector according to claim 3, and the host cell is Escherichia coli.

5. Use of the transaminase mutant according to claim 2, the recombinant vector according to claim 3, and the genetically engineered bacteria according to claim 4 in the preparation of chiral intermediates of oxaliplatin.

6. A method for preparing a chiral intermediate of oxaliplatin, It is characterized in that The following steps are involved: Step 1, using 1,2-cyclohexanediamine as a substrate, adding a catalyst containing transaminase and pyruvic acid to convert 1,2-cyclohexanediamine into 2-aminocyclohexanone, and after the catalytic reaction is completed, inactivating the transaminase; the amino acid sequence of the transaminase is shown in SEQ ID NO.1; Step 2: adding a catalyst comprising the aminotransferase mutant according to claim 2 and isopropylamine to transfer the amino group of isopropylamine to R-2-aminocyclohexanone to form (1R, 2R)-trans-1,2-cyclohexanediamine.

7. The preparation method according to claim 6, It is characterized in that In the step 1, the molar amount of pyruvic acid is 2 to 20 times that of 1,2-cyclohexanediamine.

8. The preparation method according to claim 6, It is characterized in that In the step 1, the transaminase is inactivated by heating to above 60° C., adjusting the pH to less than 4 or greater than 11, or ultrafiltration.

9. The preparation method according to claim 6, It is characterized in that The molar amount of isopropylamine in step 2 is 2 to 20 times that of 1,2-cyclohexanediamine.

Citation Information

Patent Citations

  • Method for separating chiral amine compound and intermediate thereof

    CN106905100A

  • US201616885